SE384207B - Sett att framstella nya 2-amino-1,4-dihydropyridinderivat - Google Patents

Sett att framstella nya 2-amino-1,4-dihydropyridinderivat

Info

Publication number
SE384207B
SE384207B SE7303020A SE7303020A SE384207B SE 384207 B SE384207 B SE 384207B SE 7303020 A SE7303020 A SE 7303020A SE 7303020 A SE7303020 A SE 7303020A SE 384207 B SE384207 B SE 384207B
Authority
SE
Sweden
Prior art keywords
amino
way
prepare new
dihydropyridine derivatives
dihydropyridine
Prior art date
Application number
SE7303020A
Other languages
English (en)
Swedish (sv)
Inventor
H Meyer
F Bossert
W Vater
K Stoepel
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of SE384207B publication Critical patent/SE384207B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Pyridine Compounds (AREA)
SE7303020A 1972-03-06 1973-03-05 Sett att framstella nya 2-amino-1,4-dihydropyridinderivat SE384207B (sv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE2210674A DE2210674C3 (de) 1972-03-06 1972-03-06 2-Amino-6-methyl-1,4-dihydropyridine, Verfahren zu ihrer Herstellung und sie enthaltende Arzneimittel

Publications (1)

Publication Number Publication Date
SE384207B true SE384207B (sv) 1976-04-26

Family

ID=5838026

Family Applications (1)

Application Number Title Priority Date Filing Date
SE7303020A SE384207B (sv) 1972-03-06 1973-03-05 Sett att framstella nya 2-amino-1,4-dihydropyridinderivat

Country Status (27)

Country Link
US (1) US3867393A (pl)
JP (2) JPS5720306B2 (pl)
AT (1) AT324337B (pl)
AU (1) AU468090B2 (pl)
BE (1) BE796278A (pl)
BG (1) BG23213A3 (pl)
CA (1) CA983033A (pl)
CH (1) CH580590A5 (pl)
DD (1) DD107274A5 (pl)
DE (1) DE2210674C3 (pl)
DK (1) DK136214C (pl)
ES (1) ES412322A1 (pl)
FI (1) FI56681C (pl)
FR (1) FR2183675B1 (pl)
GB (1) GB1369401A (pl)
HK (1) HK44977A (pl)
HU (1) HU167087B (pl)
IE (1) IE37369B1 (pl)
IL (1) IL41665A (pl)
LU (1) LU67148A1 (pl)
NL (1) NL7303136A (pl)
NO (1) NO140977C (pl)
PL (1) PL89258B1 (pl)
RO (1) RO61193A (pl)
SE (1) SE384207B (pl)
YU (1) YU44873A (pl)
ZA (1) ZA731503B (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3959296A (en) * 1972-06-10 1976-05-25 Bayer Aktiengesellschaft 1,4-Dihydropyridines
US3974278A (en) * 1973-07-12 1976-08-10 Bayer Aktiengesellschaft 1,4-Dihydropyridine esters
CH607848A5 (pl) * 1974-06-04 1978-11-30 Bayer Ag
DE2715182A1 (de) * 1977-04-05 1978-10-19 Bayer Ag 2-alkylenaminodihydropyridine, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
US4177278A (en) * 1977-04-05 1979-12-04 Bayer Aktiengesellschaft 2-Alkyleneaminodihydropyridines compounds, their production and their medicinal use
FI813460L (fi) * 1980-11-10 1982-05-11 Sandoz Ag Nya 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-pyridinderivat deras framstaellningsfoerfarande och dessa innehaollande farmaceutiska kompositioner
DE3208628A1 (de) * 1982-03-10 1983-09-22 Bayer Ag, 5090 Leverkusen Neue verbindungen, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
EP0125803A3 (en) * 1983-04-27 1987-01-21 FISONS plc Pharmaceutically active dihydropyridines
US4603135A (en) * 1983-10-17 1986-07-29 Takeda Chemical Industries, Ltd. Substituted piperazinyl alkyl esters of 2-amino-4-aryl-1,4-dihydro-6-alkyl-3,5-pyridinedicarboxylates
GB8620880D0 (en) * 1986-08-29 1986-10-08 Pfizer Ltd Therapeutic agents
US4912239A (en) * 1987-11-13 1990-03-27 Dow Corning Corporation Method for stabilizing unsaturated organosilicone compositions
US5455253A (en) * 1992-10-20 1995-10-03 Zeneca Limited Heterocyclic derivatives
DE4430095A1 (de) * 1994-08-25 1996-02-29 Bayer Ag Verwendung von 6-Amino-1,4-dihydropyridinen als Arzneimittel zur Behandlung des zentralen Nervensystems und Verfahren zu ihrer Herstellung
DE4444860A1 (de) * 1994-12-16 1996-06-20 Bayer Ag Verwendung von 1,2-überbrückten 1,4-Dihydropyridinen als Arzneimittel
AU2004272078A1 (en) * 2003-09-10 2005-03-24 Synta Pharmaceuticals Corp. Dihydropyridine compounds for treating or preventing metabolic disorders
US20090012103A1 (en) * 2007-07-05 2009-01-08 Matthew Abelman Substituted heterocyclic compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3325505A (en) * 1965-02-24 1967-06-13 Smith Kline French Lab 4-cycloalkyl(or cycloalkenyl)-dihydropyridines
US3511847A (en) * 1967-02-07 1970-05-12 Smithkline Corp 2,6-di-lower alkyl - 1,4-dihydro - 4-(2-trifluoromethylphenyl) - 3,5 - pyridinedicarboxylic acid esters
DE1923990C3 (de) * 1969-05-10 1978-11-23 Bayer Ag Verfahren zur Herstellung von N-substituierten M-Dihydropyridin-S.S-dicarbonsäureestern
DE2013431C3 (de) * 1970-03-20 1979-12-20 Bayer Ag, 5090 Leverkusen 4-Azidophenyl-l,4-dihydropyridin-3,5-dicarbonsäureester
DE1963188A1 (de) * 1969-12-17 1971-06-24 Bayer Ag Neue Cyanphenyl-1,4-dihydropyridinderivate
DE1963186C3 (de) * 1969-12-17 1979-02-15 Bayer Ag, 5090 Leverkusen Schwefelhaltige 1,4-Dihydropyridin-33-dicarbonsäureester
ZA7152B (en) * 1970-01-24 1971-10-27 Bayer Ag New pharmaceutically active 1,4-dihydropyridines
DE2117571C3 (de) * 1971-04-10 1979-10-11 Bayer Ag, 5090 Leverkusen Unsymmetrische 1,4-Dihydropyridin-33-dicarbonsäureester, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel
DE2117572C3 (de) * 1971-04-10 1980-03-20 Bayer Ag, 5090 Leverkusen Unsymmetrische 1,4-Dihydropyridin ^-dicarbonsäureester, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel

Also Published As

Publication number Publication date
CA983033A (en) 1976-02-03
LU67148A1 (pl) 1973-05-22
FI56681B (fi) 1979-11-30
NL7303136A (pl) 1973-09-10
PL89258B1 (pl) 1976-11-30
DE2210674A1 (de) 1973-09-13
DE2210674C3 (de) 1981-09-24
ES412322A1 (es) 1976-01-01
RO61193A (pl) 1976-10-15
DK136214B (da) 1977-09-05
JPS48103586A (pl) 1973-12-25
IE37369B1 (en) 1977-07-06
BG23213A3 (pl) 1977-07-12
JPS5720306B2 (pl) 1982-04-27
DK136214C (da) 1978-03-06
AU5287573A (en) 1975-03-27
AT324337B (de) 1975-08-25
DE2210674B2 (de) 1980-09-04
IL41665A0 (en) 1973-05-31
BE796278A (fr) 1973-09-05
AU468090B2 (en) 1975-03-27
US3867393A (en) 1975-02-18
IE37369L (en) 1973-09-06
DD107274A5 (pl) 1974-07-20
ZA731503B (en) 1973-11-28
IL41665A (en) 1975-08-31
HK44977A (en) 1977-09-09
YU44873A (en) 1982-02-25
CH580590A5 (pl) 1976-10-15
GB1369401A (en) 1974-10-09
NO140977B (no) 1979-09-10
JPS5798265A (en) 1982-06-18
FI56681C (fi) 1980-03-10
HU167087B (pl) 1975-08-28
NO140977C (no) 1979-12-19
FR2183675B1 (pl) 1976-12-03
FR2183675A1 (pl) 1973-12-21

Similar Documents

Publication Publication Date Title
SE7614680L (sv) Sett att framstella nya bensodiazepinderivat
SE421615B (sv) Sett att framstella nya tiazolderivat
SE419161B (sv) Sett att framstella nya tabletter, innehallande mikrokapslar i massan med forlengd verkan
SE7607152L (sv) Sett att framstella nya 2-piperidinoalkyl-1,4-bensdioxaner
SE403777B (sv) Sett att framstella nya 1,4-dihydropyridin-polyestrar
SE7711848L (sv) Sett att framstella nya 5-metyl-7-hydroxi-isoflavonderivat
SE384207B (sv) Sett att framstella nya 2-amino-1,4-dihydropyridinderivat
SE7507026L (sv) Nya bensimidazolinderivat.
SE411349B (sv) Sett att framstella nya penicilliner
SE410600B (sv) Sett att framstella nya arylaminopyrimidinderivat
SE397830B (sv) Sett att framstella nya bensodioxol-piperazinderivat
SE7514212L (sv) Sett att framstella nya, antendningshemmande verksamma, substituerade fenylettiksyror
SE385881B (sv) Sett att framstella nya 2-amino - 1,4-dihydropyridiner med en karbonylfunktion
NL7407132A (nl) Kamferderivaten.
SE386164B (sv) Sett att framstella nya 2-alkylamino-dihydropyridiner
SE399255B (sv) Sett att framstella kinazolinonderivat
SE7603276L (sv) Sett att framstella prostansyraderivat
SE7505595L (sv) Sett att framstella abietamidderivat.
SE400078B (sv) Sett att framstella kinazolinonderivat
SE399712B (sv) Sett att framstella pregnansyraderivat
SE7509209L (sv) Sett att framstella nya kinolinderivat
ES430319A0 (es) Procedimiento para preparar derivados de piperidina.
SE384208B (sv) Sett att framstella nya 2,6-diamino-dihydropyridiner
SE413022B (sv) Sett att framstella nya propylendiaminderivat
SE400281B (sv) Sett att framstella kinazolinonderivat